PetVivo Holdings, Inc. (OTCQB: PETV), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics, is pleased to provide an update on the Kush study results for treating animal osteoarthritis.
"We continue advancing our Kush device for the treatment of animal lameness," noted PetVivo CEO John Lai "I am excited about our Kush device, demonstrating great safety data for over eight years in five species, including people. The case-study reports to treat bad joints in horses, started 3 years ago, and dogs, started 6 months ago, have been very positive."
PetVivo has licensed the Kush device from Gel-Del Technologies, Inc. and is planning a launch in Q4 of this year.
Gel-Del CEO Dr. David Masters reported, "Our Kush case-study observations are very encouraging, especially since to date we have only treated horses and dogs with severe osteoarthritis and lameness. These horses and dogs have all tolerated the particle joint injection treatments extremely well. In fact, after filling joint spaces in the lower limbs of horses and in the elbow and/or knee joints of dogs, we are seeing improved mobility and gait characteristics, and a reduction or elimination of pain meds in all animals treated. We are experiencing strong owner satisfaction that has resulted in additional Kush treatments to other afflicted joints in their pets."
The two companies have previously announced that they have signed a term sheet to merge. Under the agreed upon terms Gel-Del will merge with PetVivo Holdings, Inc. and upon resolution of certain conditions specified as terms, a definitive agreement will consummate the merger. Dr. Masters noted, "I am looking forward to our merger so that we can address many unmet needs in veterinary and human patients."
About PetVivo, Inc:
PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCQB: PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.
PetVivo, Inc. believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
The fore-going material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Chief Executive Officer
PetVivo Holdings, Inc.
SOURCE: PetVivo Holdings, Inc.